# US 2020/0390784 A1 · Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390784 A1
- Document ID: US20200390784A1
- Status: Published application
- Kind: A1
- Application number: 16/696,159
- Filed: 2019-11-26
- Published: 2020-12-17
- Earliest claimed: 2009-12-31
- Assignees: Marius Pharmaceuticals LLC
- Applicants: Marius Pharmaceuticals LLC
- Inventors: Om DHINGRA
- Web page: https://patentgrep.com/patent/US20200390784A1

## CPC

- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 5/26: Androgens
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of treating sexual dysfunction in a woman, the method comprising orally administering to the woman an oral formulation comprising solubilized testosterone palmitate.

### Claim 3

A method of improving muscle strength in a subject, the method comprising transdermally administering to the subject testosterone bucyclate.

### Claim 4

An oral formulation comprising:
a) testosterone undecanoate;
b) a non-sterol solubilizing agent effective for solubilization of the testosterone undecanoate; and
c) a phytosterol or phytosterol ester.

### Claim 5 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation comprises from 40 to 400 mg of testosterone undecanoate.

### Claim 6 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation comprises from 0.1 to 40% by weight testosterone undecanoate.

### Claim 7 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation comprises from about 2% to about 45% by weight phytosterol or phytosterol ester.

### Claim 8 (depends on 4)

The oral formulation of claim 4, wherein the non-sterol solubilizing agent comprises propylene glycol monolaurate.

### Claim 9 (depends on 4)

The oral formulation of claim 4, wherein the non-sterol solubilizing agent comprises polyoxyl 40 hydrogenated castor oil.

### Claim 10 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation comprises:
a) from 0.1 to 40% by weight testosterone undecanoate;
b) from about 10% to about 90% by weight a non-sterol solubilizing agent effective for solubilization of the testosterone undecanoate; and
c) from about 2% to about 45% by weight a phytosterol or phytosterol ester.

### Claim 11 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation is self-emulsifying or self-microemulsifying.

### Claim 12 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation further comprises alpha-tocopherol or alpha-tocopherol acetate.

### Claim 13 (depends on 4)

The oral formulation of claim 4, wherein the oral formulation comprises phytosterol esters.

### Claim 14 (depends on 4)

A method of treating male hypogonadism in a subject in need thereof, the method comprising administering to the subject the oral formulation of claim 4.

### Claim 15 (depends on 14)

The method of claim 14, wherein the oral formulation comprises from 40 to 400 mg of testosterone undecanoate.

### Claim 16 (depends on 14)

The method of claim 14, wherein the oral formulation comprises from 0.1 to 40% by weight testosterone undecanoate.

### Claim 17 (depends on 14)

The method of claim 14, wherein the oral formulation comprises from about 2% to about 45% by weight phytosterol or phytosterol ester.

### Claim 18 (depends on 14)

The method of claim 14, wherein the non-sterol solubilizing agent comprises propylene glycol monolaurate.

### Claim 19 (depends on 14)

The method of claim 14, wherein the non-sterol solubilizing agent comprises polyoxyl 40 hydrogenated castor oil.

### Claim 20 (depends on 14)

The method of claim 14, wherein the oral formulation further comprises alpha-tocopherol or alpha-tocopherol acetate.

### Claim 21 (depends on 14)

The method of claim 14, wherein the oral formulation comprises:
a) from 0.1 to 40% by weight testosterone undecanoate;
b) from about 10% to about 90% by weight a non-sterol solubilizing agent effective for solubilization of the testosterone undecanoate; and
c) from about 2% to about 45% by weight a phytosterol or phytosterol ester.
